ABSTRACT

Background

Fracture nonunions impact on morbidity and health care costs and are associated with substantial pain, reduced mobility, prolonged morbidity, and a lower quality of life. CMF OrthoLogic 1000 (OL1000) is a bone growth stimulator used to promote fracture healing potentially reducing the need for surgical intervention. A cost analysis comparing CMF OL1000 versus surgical care for patients with nonunion tibial fractures was conducted.

Methods

A Markov model was developed to compare the difference in costs between CMF OL1000 versus surgical care within the English National Health Service over a 2-year time horizon. The effectiveness of CMF OL1000 was based on recently published registry data. Cost data were derived from published sources and national cost databases. Sensitivity and scenario analyses were conducted.

Results

The use of CMF OL1000 is estimated to lead to cost-savings of £1,104 per patient, a reduction in average healing time of 2.1 months and a relative risk of infection of 0.19 compared to immediate surgical intervention (standard of care). The results of the model are robust to most changes in input parameters and scenarios considered.

Conclusions

This early analysis shows cost-savings for CMF OL1000 compared with surgical intervention for individuals with nonunion tibial fractures.

中文翻译：

---

英国磁力骨生长刺激的早期成本分析

摘要

背景

骨折不愈合会影响发病率和医疗保健费用，并与严重的疼痛、行动不便、发病率延长和生活质量降低有关。CMF OrthoLogic 1000 (OL1000) 是一种骨骼生长刺激器，用于促进骨折愈合，从而可能减少手术干预的需要。进行了比较 CMF OL1000 与手术治疗胫骨骨不连骨折患者的成本分析。

方法

开发了一个马尔可夫模型来比较 CMF OL1000 与英国国民健康服务体系内外科治疗在 2 年时间范围内的成本差异。CMF OL1000 的有效性基于最近公布的注册数据。成本数据来自已发表的来源和国家成本数据库。进行了敏感性和情景分析。

结果

据估计，与立即手术干预（护理标准）相比，使用 CMF OL1000 可为每位患者节省 1,104 英镑的成本，平均愈合时间减少 2.1 个月，感染的相对风险为 0.19。该模型的结果对于所考虑的输入参数和场景的大多数变化都是稳健的。

结论

这项早期分析表明，与手术干预相比，CMF OL1000 对胫骨骨不连骨折患者的成本节约。